Vincerx Pharma Inc (VINC) concluded trading on Wednesday at a closing price of $1.56, with 18.0 million shares of worth about $28.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -88.00% during that period and on January 29, 2025 the price saw a loss of about -5.45%. Currently the company’s common shares owned by public are about 1.57M shares, out of which, 1.50M shares are available for trading.
Stock saw a price change of -29.98% in past 5 days and over the past one month there was a price change of -57.59%. Year-to-date (YTD), VINC shares are showing a performance of -70.32% which decreased to -93.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.62 but also hit the highest price of $187.44 during that period. The average intraday trading volume for Vincerx Pharma Inc shares is 394.23K. The stock is currently trading -54.14% below its 20-day simple moving average (SMA20), while that difference is down -62.46% for SMA50 and it goes to -85.64% lower than SMA200.
Vincerx Pharma Inc (NASDAQ: VINC) currently have 1.57M outstanding shares and institutions hold larger chunk of about 30.24% of that.
The stock has a current market capitalization of $3.49M and its 3Y-monthly beta is at 1.08. It has posted earnings per share of -$20.62 in the same period. It has Quick Ratio of 2.17 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VINC, volatility over the week remained 18.94% while standing at 19.46% over the month.
Stock’s fiscal year EPS is expected to rise by 59.79% while it is estimated to increase by 39.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it. Coverage by Cantor Fitzgerald stated Vincerx Pharma Inc (VINC) stock as an Overweight in their note to investors on December 23, 2021, suggesting a price target of $25 for the stock. On November 01, 2021, SVB Leerink Initiated their recommendations, while on September 13, 2021, Laidlaw Initiated their ratings for the stock with a price target of $30. Stock get a Buy rating from B. Riley Securities on August 25, 2021.
